Interesting the slide on manufacturing and toxicity measurements. If they really have everything sorted for manufacturing by end 2016 that's a real achievement. You can argue if Ph III doesn't get up it's money down the drain (see ACL) but to me it's prudent risk management to get this sorted out now.
I'm really looking forward to the AGM this year. If TBI gets up it'll be a corker.
Ann: Neuren Investor Presentation, 11 January 2016, page-6
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.20 |
Change
0.890(6.69%) |
Mkt cap ! $1.761B | |||
| Open | High | Low | Value | Volume |
| $13.50 | $14.26 | $12.96 | $9.111M | 655.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $14.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.23 | 3278 | 1 |
View Market Depth
| Last trade - 16.15pm 27/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |